The trend toward decriminalization of cannabis (marijuana) continues sweeping across the United States. Colorado has been a leader of legalization of medical and recreational cannabis use. The growing public interest in the medicinal properties of cannabis and its use by patients with a variety of illnesses including inflammatory bowel disease (IBD) makes it important for pediatric gastroenterologists to understand this movement and its potential effect on patients. This article describes the path to legalization and ''medicalization'' of cannabis in Colorado and the public perception of safety despite the known adverse health effects of use. We delineate the mammalian endocannabinoid system and our experience of caring for children and adolescents with IBD in an environment of increasing awareness and acceptance of its use. We then summarize the rationale for considering that cannabis may have beneficial and harmful effects for patients with IBD. Finally, we highlight the challenges federal laws impose on conducting research on cannabis in IBD. The intent of this article is to inform health care providers about the issues around cannabis use and research in adolescents and young adults with IBD.
s of fall 2015, Colorado was one of 24 states that legalized cannabis use for medical purposes and one of 4 states that allowed adult use for recreational purposes (1) . The passage of Amendment 20 in 2000 allowed adult Colorado residents with valid social security numbers and diagnosed with certain debilitating conditions or undergoing treatment for specific conditions to have possession of up to 2 ounces, and to grow up to 6 cannabis plants, for medicinal purposes. An identification card was required, and a doctor recommendation to use cannabis as treatment for these conditions (Table 1) . A minor could receive a cannabis recommendation with consent of both parents and documentation from 2 physicians (3). Parents could then apply for a medical marijuana card on behalf of their child, be listed as the child's caregiver on the card, and have permission to transport medical marijuana from a medical marijuana dispensary to their child. In this way, Colorado voters defined cannabis as an acceptable treatment for a number of chronic conditions that produce subjective symptoms such as severe pain or nausea, and for cachexia (4) .
With abolishment of the limitation of 5 ''patients'' to 1 ''caregiver'' and the US Department of Justice indicating they would not likely prosecute individuals in compliance with state laws, applications for medical marijuana increased from 6000 in 2008 to 100,000 in 2012 and there were approximately 500 licensed dispensaries providing legal medical marijuana (5) . In the vast majority (>90%) the medical indication was severe pain. In 2012, Colorado voters enacted state constitutional Amendment 64, which legalized recreational cannabis use for those older than 20 years and provided for a system for regulation, taxation, and distribution, similar to alcohol. The expansion of the cannabis industry began in earnest in 2013. The first retail stores opened on January 1, 2014. In 2015, Colorado had $1 billion in sales, generating an expected $100 million in tax revenue, double that of 2014 (6) . For 2015, approximately 40% of revenue came from medical, and 60% from recreational use. Recreational cannabis, because of additional excise taxes designated to provide funds for schools and other projects, is more
What Is Known
Cannabis use is increasingly accepted across the United States. There is public perception of the medical benefits of cannabis to treat many chronic diseases including inflammatory bowel disease, but little concern about safety.
What Is New
Approximately one quarter of adolescents and young adults with inflammatory bowel disease in Colorado use cannabis regularly. Although there is rationale for considering that cannabis may be helpful, there are unique aspects to conducting research on cannabis in pediatric patients with inflammatory bowel disease.
expensive than medical cannabis. Many habitual users still purchase the cheaper medical marijuana.
There is a process by which cannabis may be given to children younger than 18 years of age in Colorado. Two physicians must diagnose the patient with a qualifying debilitating condition, one of which must explain the possible risks and benefits in writing (there are no state guidelines on what this should include), and a parent must be a primary care giver. The state then provides the parent with a medical marijuana minor patient card. The amount that may be possessed is much higher for medical than for recreational purposes. A number of families have moved to Colorado, specifically to obtain cannabidiol (CBD) oil to treat severe seizures and neurologic conditions in their children (7) .
Colorado has embarked on a social experiment ''medicalizing'' cannabis use and ending prohibition on recreational use. In its current state, the industry may be viewed as much like a pharmaceutical company that is in both production and retail. The product, however, is not one well-tested drug, but may contain more than 100 chemicals in varying amounts, provided in different types of delivery systems (smoking, vaping, edibles, patches, oils, etc), and with mainly anecdotal data on efficacy for treating human disease and an absence of information on safety and drug interactions. Health care providers will be asked by patients to discuss the medical marijuana issues (8) .
PUBLIC PERCEPTION OF RISK AND ADVERSE EFFECTS
The public perception of risk is quite low. In the ''Monitoring the Future'' report, the proportion of high school seniors who view regular use of cannabis as not having great risk was 60% in 2014, a figure that has been increasing steadily since 2004 (9) . Substantial literature, however, supports the view of significant adverse health effects with both short-term and long-term use, mainly on neurologic, cognitive, and mental health (Table 2) (10,11). There may be acute psychotic symptoms during intoxication, and several cases of apparent acute intoxication have been widely reported in the local media, including one 19-year-old who jumped off a hotel balcony to his death, and a husband who shot his wife (12) . Impaired adolescent driving while intoxicated with cannabis, especially in combination with alcohol, is another important issue. There has been an increase in the potency of tetrahydrocannabinol (THC) content in marijuana from approximately 3% in the 1980s to 12% in 2012 (13) , raising concerns about the effect of this increased potency on the potential adverse effects of marijuana use. Another major concern is that cannabis ingested in an edible form is more difficult to titrate, unlike vaping or inhaling, as the effect may be delayed, and therefore higher doses may be consumed leading to intoxication. Heavy users have impaired memory for at least 1 week after abstinence; hyperemesis syndrome has been well described as have withdrawal symptoms. Addiction risk may be higher for those beginning heavy use in adolescence, and this behavior may predict progression to harder drugs (10, 14) . These negative effects have both immediate and long-term implications, leading the American Academy of Pediatrics (15) and the Academy of Child and Adolescent Psychiatry (16) to officially oppose the legalization of marijuana. These issues have not been widely reported in the public media. There are, however, particular challenges in interpreting the literature on cannabis use, because the data are often derived from studies of heavy and/or long-term users where there are other potential confounding factors, such as use of other drugs, psychosocial, and economic adversity (10) . Furthermore, the retrospective and correlational methodologies used do not allow for inferences of causality for any adverse outcomes associated with cannabis use.
CLINICAL USE OF CANNABINOIDS AND SIDE EFFECTS
A rigorously conducted meta-analysis of randomized clinical trials of cannabinoids (CBs) across a broad range of conditions found only 4 of 79 randomized clinical trials to have a low risk of bias (17) , with 70% of studies having a high risk of bias, typically due to incomplete outcome data. The large majority of trials evaluated chemotherapy-related nausea and vomiting, chronic pain, and spasticity due to multiple sclerosis or paraplegia. Use of CBs for chronic pain and spasticity was supported by moderate-quality evidence. Improvements in chemotherapy-related nausea and vomiting, weight gain in HIV, sleep disorders, and Tourette syndrome were supported by low-quality evidence. Overall CBs were associated with an increased risk of adverse effects, with an odds ratio (OR) of any adverse effect of 3.03 (95% confidence interval [CI]: 2.42-3.80) and serious adverse effects, OR of 1.41 (95% CI: 1.04-1.92). There is a dearth of evidence related to clinical trials of cannabis itself, including associated adverse effects. As public acceptance of cannabis expands, some states have included in the legalization process that tax funds be allocated to address the lack of scientific knowledge on potential beneficial and harmful effects of use. 
MAMMALIAN ENDOCANNABINOID SYSTEM
Cannabis affects humans through crossreactivity with an endogenous mammalian CB-sensing system known as the endocannabinoid system. This system includes receptors active in the central and peripheral nervous system (where they modulate appetite, pain, mood, and memory) and in many peripheral organs, including the gastrointestinal tract (where it may affect motility and secretion via acetylcholine) (18) (Fig. 1) .
The most well-known receptors are the G-protein coupled CB1 and CB2 receptors. CB1 receptor expression is found primarily in the nervous system, whereas CB2 receptors may be found on immune cells where they modulate immune cell function. Additional atypical receptors, such as TRPV1 and GPR55 have been reported to be responsive to endocannabinoids, but their functions are still being clarified. The primary endogenous ligand for the CB1 receptor is anandamide, and the primary endogenous ligand for the CB2 receptor is 2-arachidonoylglycerol (19) . THC has greater affinity for the CB1 receptor than for the CB2 receptor and CBD has a weak affinity for CB2 receptor. Both anandamide and 2-arachidonoylglycerol are metabolized by the arachidonic acid pathway (18) (Fig. 2) .
WHAT IS IN CANNABIS?
The cannabis plant is composed of stem, leaves, nodes, and male or female flowers. The male cannabis flowers pollinate the female plants, whereas female flowers provide the CBs for consumption. There are more than 106 known phytocannabinoid chemicals identified from the cannabis plant (20) . The 2 main active ingredients of cannabis are THC, the primary psychoactive substance, and CBD), a largely nonpsychoactive substance. Not only may plant products be present, but pesticides and fungi sometimes are found as well (21) .
Depending on whether there are buds, leaves, and stems, the amount of THC, CBD, and other chemical components varies greatly. Many strains for recreational use have an abundance of THC, which induces both psychoactive and soporific effects, whereas CBD abundant strains such as Charlotte's Web are less common, but gaining popularity due to the antiseizure, anxiolytic, nonpsychotropic effects. Epidiolex, a liquid formulation from GW Pharmaceuticals that contains pure, plant-derived CBD has received Fast Track designation from the Food and Drug Administration due to its promising investigation trial in Dravet syndrome, a severe, refractory, infantile-onset form of epilepsy.
PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS USE CANNABIS
Patients and parents ask our opinion about trying cannabis for their IBD symptoms. From surveys we have conducted, we know that some of our patients in the pediatric IBD center at Children's Hospital Colorado use cannabis (22) . They report to us trying cannabis in multiple forms, including smoking, edibles, and CBD oil. Patients and parents tell us they feel it helps treat their IBD beyond improved coping, decreased pain, and better appetite. Furthermore, patients have asked us for a medical marijuana card, however, none in our group have completed a Physician Certification form required to formally recommend medical marijuana (4).
It
DO OUR INFLAMMATORY BOWEL DISEASE PATIENTS USE CANNABIS SIMILARLY TO PEERS WITHOUT CHRONIC ILLNESS?
Given our IBD patient's interest in and use of legal medical and recreational cannabis in Colorado, we conducted a pilot study to measure use in 65 pediatric subjects with IBD and 100 subjects without chronic illness (22) . Using the validated Composite International Diagnostic Interview-Substance Abuse Module questionnaire (23, 24) , we found that frequency of ever using cannabis was similar between the groups (IBD 31% and control 40%, P ¼ NS). IBD users, however, reported weekly or more use much more frequently (IBD 55% and control 26%, OR 3.54 95% CI 1.14-11.05, P ¼ 0.03). Motivation for use was also different; the IBD group reported cannabis use more frequently for treatment of physical symptoms.
How do our results compare to state and national data? The Healthy Kids Colorado Survey (25) and the Youth Risk Behavioral Survey (26) provide this information. In 2013, both Colorado and National data show that about 40% of high school students had ever used cannabis, similar to our IBD and control groups. In terms of intensity of use, the Healthy Kids Colorado Survey and Youth Risk Behavioral Survey report approximately 20% to 25% use weekly or more. Again, our study's comparison group, at 26%, was consistent with these data, whereas our IBD group, at 55%, was much higher. There are alarming national data (27) that daily or almost daily use of cannabis among 12-to 17-year-olds is increasing rapidly. In 2003, 4.9 million Americans 12 years and older reported daily cannabis use for the past month; by 2013 it was 8.1 million.
We can summarize US trends for cannabis use:
1. Increase in daily use 2. Increase in potency 3. Continued and growing popular belief in the safety and possible benefits of regular consumption 4. Pediatric patients with IBD who use cannabis may do so more intensely and for physical reasons, compared with peers without chronic illness.
CANNABIS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
We could identify no studies evaluating cannabis for the treatment of IBD in children and data in adults are limited. There are 3 observational studies of approximately 300 adult subjects, which suggest that use of cannabis is associated with subjective relief of symptoms (28) (29) (30) .
A single placebo-controlled clinical trial of THC was conducted for treatment of Crohn disease. Patients smoked cigarettes with known THC content or placebo, and at 8 weeks, 10 of 11 in the cannabis group showed a response with a drop in Crohn's Disease Activity Index, compared to 4 of 10 in the placebo group (P ¼ 0.028) (31) . Whether there is a disease modifying benefit, as opposed to an enhanced quality of life is unknown. And whether the effect is long lasting has also not been studied.
POTENTIAL BENEFICIAL MECHANISMS OF CANNABIS IN INFLAMMATORY BOWEL DISEASE
Cannabis can potentially be used to alleviate a number of IBD-associated intestinal symptoms, including reducing nausea, stool frequency, and abdominal pain, and improving appetite and weight gain (8, 32, 33 ). This in turn may indirectly influence intestinal inflammation and possibly microbiome. However, it remains unclear whether or not it has any direct effect on the underlying disease pathogenesis. We do know that the endogenous CB system (including CB receptors and the cognate ligand anandamide) is upregulated in patients with ulcerative colitis (34, 35) suggesting a role in disease regulation. Moreover, anandamide has been shown to suppress proliferation and cytokine release from primary human T-lymphocytes mainly via the CB2 receptor (36) . CBD may exert anti-inflammatory effects through inhibition of fatty acid amidohydrolase, which leads to increased concentrations of anandamide (37) .
The primary psychoactive ingredient in cannabis, THC, acts mainly as a weak CB1 receptor agonist. Through this pathway, THC can also inhibit human T-cell proliferation, preferentially targeting the same proinflammatory interferon-g-producing Th1 cells that are heavily implicated in IBD pathogenesis (38) . THC also, however, increases the concentration of regulatory T-cellÀassociated cytokines, interleukin-10 and transforming growth factor-b, in unfractionated human T-cell cultures (39) suggesting that the capacity of THC to reduce T-cell proliferation may actually reflect the ability to enhance regulatory T-cell suppressive function. This could be particularly beneficial in the context of IBD given the established impaired regulatory T-cell suppressive function associated with this disease (40) . One concern with the administration of CBs in the context of inflammation and increased endocannabinoid production is the potential for receptor desensitization, which can occur in the case of the human immune-associated CB2 receptor (41) . Although anandamide and THC may both have beneficial effects in isolated short-term cell culture experiments, it remains to be seen if the chronic combination has synergistic or contradictory effects in vivo.
In addition to potential T-cell targeted anti-inflammatory mechanisms, CBs have also been shown to impair cytokine production by human neutrophils, and in particular the IBD-associated proinflammatory cytokine tumor necrosis factor-a (42) . Human neutrophil transmigration in vitro is also impaired by treatment with synthetic cannabinomimetics, although the mechanism, while unclear, does not appear to be mediated via the CB1 or CB2 receptor, suggesting that it may have been an indirect effect. Although neutrophils are relatively short-lived, they are widely considered to be critical to the acute phase of intestinal injury associated with IBD. Clearly, our overall understanding of potential anti-inflammatory mechanisms of cannabis is relatively poor. This is compounded by the wide array of biologically active components found in cannabis, which include agonists, antagonists, partial agonists, positive allosteric modulators, and negative allosteric modulators. A clinical trial sponsored by Bial, a pharmaceutical company in Portugal, and conducted by the French company Biotrial, studied the effect in human volunteers of a fatty acid amide hydrolase inhibitor, an enzyme that is thought to break down endocannabinoids in the brain. The study was aborted after 5 of 6 subjects receiving the highest doses developed significant neurologic adverse effects including 1 death (43) . Although this effect was not believed to be a drug class effect, it highlights that further study is essential to determine the possible effect and safety of CBs before their use for the treatment of IBD.
CHALLENGES WITH CANNABIS IN HUMAN SUBJECT RESEARCH
With the legalization of medical and recreational cannabis and implementation of a regulatory system, one would expect that this recent change to the law would open new opportunities for human subject research involving cannabis. In fact, we have obtained a grant from the Colorado Department of Public Health and Environment to perform an observational study to evaluate cannabis in pediatric inflammatory bowel disease (IBD). Academic researchers in Colorado now face some paradoxical challenges because under federal law, cannabis continues to remain a Schedule 1 drug.
To start with, there is still some uncertainty about the future of legalized cannabis in Colorado. On August 29, 2013, the Department of Justice released an update to the Marijuana Enforcement Policy (44), restating its efforts on enforcement priorities related to cannabis and the Department's expectation that States that legalize cannabis would establish strict regulatory schemes that protect these federal enforcement priorities. This policy was based on assurance from the Colorado governor that these schemes will be in strict adherence and include strong state-based enforcement efforts that are backed by adequate funding. But the Department of Justice clearly states that it reserves the right to challenge the State's legalization in the future.
There is also a continuing risk to be involved in litigation. Throughout 2015, several Colorado private businessmen operating cannabis businesses that were authorized under State law, and businesses that financed, insured, built, and funded these businesses, were sued under the allegation that they constitute criminal enterprises under the Racketeer Influenced and Corrupt Organization Act (45) .
Furthermore, a careful review of funding sources for research involving cannabis is critical because the Controlled Substances Act and other laws, such as the Anti-Money Laundering law, prohibit everyone from dealing with the proceeds from Controlled Substances, or from engaging in financial transactions with these proceeds.
For universities receiving Title IV federal student aid funding, the Drug-Free Schools and Campuses Regulations (EDGAR Part 86) require the implementation of a program to prevent the unlawful possession, use, or distribution of illicit drugs and alcohol by students and employees, and a policy that stipulates that a student or employee who violates the alcohol and other drugs policy is subject to both the institution's sanction and to criminal sanction provided by federal, state, and local law. This again creates a challenging environment for academic researchers who want to study health effects of cannabis.
Researchers who plan to conduct a scientifically designed, interventional study with cannabis have additional challenges. First, in the United States, National Institute on Drug Abuse, the federal agency overseeing marijuana for human subject research, contracts with the University of Mississippi to grow the only current supply of marijuana for use in human research studies (46) . Second, even Given all of the above challenges, our institution developed still evolving guidelines for human subject research involving cannabis (Table 3) . We also identified a number of important issues that are yet to be resolved (Table 4) . We recommend ongoing monitoring of federal and state laws as the field evolves.
CONCLUSIONS
Recreational and medical cannabis use is increasing in the United States. There is an incorrect public perception of the safety of regular use. Approximately 30% to 40% of adolescents and young adults with IBD will try cannabis and some report benefit for their IBD. There is some rationale for considering a possible immune modifying effect of cannabis on IBD. The possible benefits and significant risks need to be better understood. The current regulatory environment, imposes unique challenges on performing rigorous research into cannabis use. Care providers should become familiar with the issues around cannabis use and maintain open communication with their pediatric patients with IBD.
